DIABETIC KETOACIDOSIS ASSOCIATED WITH EMPAGLIFLOZIN THERAPY : MECHANISMS, RISC FACTORS AND CLINICAL IMPLICATIONS. ijai [Internet]. 2025 Sep. 5 [cited 2026 Mar. 15];5(09):221-3. Available from: https://www.academicpublishers.org/journals/index.php/ijai/article/view/6299